Denali Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Thomas Shrader from BTIG maintained a Buy rating on the stock and has a $39.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Thomas Shrader has given his Buy rating due to a combination of factors, including the transformative profile of AVLAYAH and the strategic positioning of Denali’s broader pipeline. AVLAYAH’s accelerated approval for neurologic manifestations of Hunter syndrome and its rapid uptake support the view that it offers a markedly better clinical outcome than existing therapies, with biomarker normalization suggesting the potential for near-normal life expectancy in a population where adult survival is currently rare.
Shrader also highlights the initiation of the first-in-human study of DNL628, a BBB-shuttled anti-tau ASO, as a pivotal validation of Denali’s OTV platform and its capacity to unlock a wide range of CNS targets. Combined with full ownership of DNL593 in FTD-GRN following Takeda’s exit, a substantial $1.05B cash position, and a clear regulatory path established by AVLAYAH, he sees a compelling risk–reward profile that justifies maintaining a $39 price target and a Buy recommendation.
In another report released on May 8, Bank of America Securities also reiterated a Buy rating on the stock with a $31.00 price target.